Brenda Gaydos

1.7k total citations
21 papers, 1.2k citations indexed

About

Brenda Gaydos is a scholar working on Statistics and Probability, Immunology and Management Science and Operations Research. According to data from OpenAlex, Brenda Gaydos has authored 21 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Statistics and Probability, 8 papers in Immunology and 6 papers in Management Science and Operations Research. Recurrent topics in Brenda Gaydos's work include Statistical Methods in Clinical Trials (15 papers), Biosimilars and Bioanalytical Methods (8 papers) and Diabetes Treatment and Management (6 papers). Brenda Gaydos is often cited by papers focused on Statistical Methods in Clinical Trials (15 papers), Biosimilars and Bioanalytical Methods (8 papers) and Diabetes Treatment and Management (6 papers). Brenda Gaydos collaborates with scholars based in United States, United Kingdom and Switzerland. Brenda Gaydos's co-authors include Michael Krams, Paul Gallo, Leigh J. Beglinger, Eric Siemers, David A. Kareken, José Cirı́aco Pinheiro, Christy Chuang‐Stein, Vladimir Dragalin, Rebecca A. Wright and Darryle D. Schoepp and has published in prestigious journals such as Diabetes Care, Diabetes Obesity and Metabolism and Journal of Psychopharmacology.

In The Last Decade

Brenda Gaydos

21 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brenda Gaydos United States 14 538 239 231 188 177 21 1.2k
Roy Tamura United States 29 542 1.0× 143 0.6× 166 0.7× 201 1.1× 104 0.6× 82 2.7k
László Tóthfalusi Hungary 25 415 0.8× 240 1.0× 140 0.6× 306 1.6× 244 1.4× 83 1.5k
Oleksandr Sverdlov United States 15 422 0.8× 124 0.5× 184 0.8× 65 0.3× 27 0.2× 58 815
Hua Jin China 14 164 0.3× 85 0.4× 58 0.3× 69 0.4× 52 0.3× 43 1.5k
Gregory G. Enas United States 13 201 0.4× 66 0.3× 19 0.1× 138 0.7× 314 1.8× 25 1.6k
Jacques Demotes‐Mainard France 25 43 0.1× 209 0.9× 14 0.1× 275 1.5× 257 1.5× 93 2.0k
David J. DeBrota United States 18 113 0.2× 77 0.3× 74 0.3× 29 0.2× 39 0.2× 26 948
Ch Davis United States 12 105 0.2× 64 0.3× 10 0.0× 174 0.9× 90 0.5× 15 1.2k
Mary F. Johnson United States 14 77 0.1× 45 0.2× 22 0.1× 655 3.5× 692 3.9× 26 1.4k
Haiyan Xu United States 15 84 0.2× 92 0.4× 33 0.1× 117 0.6× 50 0.3× 30 936

Countries citing papers authored by Brenda Gaydos

Since Specialization
Citations

This map shows the geographic impact of Brenda Gaydos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brenda Gaydos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brenda Gaydos more than expected).

Fields of papers citing papers by Brenda Gaydos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brenda Gaydos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brenda Gaydos. The network helps show where Brenda Gaydos may publish in the future.

Co-authorship network of co-authors of Brenda Gaydos

This figure shows the co-authorship network connecting the top 25 collaborators of Brenda Gaydos. A scholar is included among the top collaborators of Brenda Gaydos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brenda Gaydos. Brenda Gaydos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hoogwerf, Byron J., et al.. (2016). Perspectives on Some Controversies in Cardiovascular Disease Risk Assessment in the Pharmaceutical Development of Glucose-Lowering Medications. Diabetes Care. 39(Supplement_2). S219–S227. 9 indexed citations
2.
Geiger, Mary Jane, Cyrus R. Mehta, J. Rick Turner, et al.. (2014). Clinical Development Approaches and Statistical Methodologies to Prospectively Assess the Cardiovascular Risk of New Antidiabetic Therapies for Type 2 Diabetes. Therapeutic Innovation & Regulatory Science. 49(1). 50–64. 14 indexed citations
3.
Morgan, Caroline, Susan Huyck, Martin Jenkins, et al.. (2014). Adaptive Design: Results of 2012 Survey on Perception and Use. Therapeutic Innovation & Regulatory Science. 48(4). 473–481. 46 indexed citations
4.
Skrivanek, Zachary, Brenda Gaydos, Jenny Y. Chien, et al.. (2014). Dose‐finding results in an adaptive, seamless, randomized trial of once‐weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD‐5). Diabetes Obesity and Metabolism. 16(8). 748–756. 49 indexed citations
5.
Luo, Junxiang, et al.. (2014). A Clinical Utility Index for Selecting an Optimal Insulin Dosing Algorithm for LY2605541 in Patients with Type 2 Diabetes Pretreated with Basal Insulin. Diabetes Technology & Therapeutics. 16(8). 499–505. 1 indexed citations
6.
Wendelberger, Joanne, Alyson G. Wilson, Sandra S. Stinnett, & Brenda Gaydos. (2014). Working in Interdisciplinary Teams. CHANCE. 27(4). 31–33. 1 indexed citations
7.
Geiger, Mary Jane, Zachary Skrivanek, Brenda Gaydos, et al.. (2012). An Adaptive, Dose-Finding, Seamless Phase 2/3 Study of a Long-Acting Glucagon-like Peptide-1 Analog (Dulaglutide): Trial Design and Baseline Characteristics. Journal of Diabetes Science and Technology. 6(6). 1319–1327. 20 indexed citations
8.
Gaydos, Brenda, Armin Koch, Frank Miller, et al.. (2012). Perspective on adaptive designs: 4 years European Medicines Agency reflection paper, 1 year draft US FDA guidance – where are we now?. Clinical Investigation. 2(3). 235–240. 9 indexed citations
9.
Skrivanek, Zachary, Scott Berry, Donald A. Berry, et al.. (2012). Application of Adaptive Design Methodology in Development of a Long-Acting Glucagon-like Peptide-1 Analog (Dulaglutide): Statistical Design and Simulations. Journal of Diabetes Science and Technology. 6(6). 1305–1318. 18 indexed citations
10.
Colvin, Kelly M., et al.. (2012). Operational Challenges and Solutions with Implementation of an Adaptive Seamless Phase 2/3 Study. Journal of Diabetes Science and Technology. 6(6). 1296–1304. 12 indexed citations
11.
Gaydos, Brenda, et al.. (2010). Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development. Clinical Trials. 7(2). 167–173. 44 indexed citations
12.
Gaydos, Brenda, Keaven M. Anderson, Donald A. Berry, et al.. (2009). Good Practices for Adaptive Clinical Trials in Pharmaceutical Product Development. Drug Information Journal. 43(5). 539–556. 63 indexed citations
13.
Krams, Michael, Carl‐Fredrik Burman, Vladimir Dragalin, et al.. (2007). Adaptive Designs in Clinical Drug Development: Opportunities, Challenges, and Scope Reflections Following PhRMA's November 2006 Workshop. Journal of Biopharmaceutical Statistics. 17(6). 957–964. 21 indexed citations
14.
Bornkamp, Björn, Frank Bretz, Alex Dmitrienko, et al.. (2007). Innovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials. Journal of Biopharmaceutical Statistics. 17(6). 965–995. 125 indexed citations
15.
Gaydos, Brenda, Michael Krams, Inna Perevozskaya, et al.. (2006). Adaptive Dose-Response Studies. Drug Information Journal. 40(4). 451–461. 34 indexed citations
16.
Gallo, Paul, Christy Chuang‐Stein, Vladimir Dragalin, et al.. (2006). Rejoinder. Journal of Biopharmaceutical Statistics. 16(3). 311–312. 2 indexed citations
17.
Gallo, Paul, Christy Chuang‐Stein, Vladimir Dragalin, et al.. (2006). Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group. Journal of Biopharmaceutical Statistics. 16(3). 275–283. 197 indexed citations
18.
Beglinger, Leigh J., Brenda Gaydos, Kevin Duff, et al.. (2005). Practice effects and the use of alternate forms in serial neuropsychological testing. Archives of Clinical Neuropsychology. 20(4). 517–529. 275 indexed citations
19.
Beglinger, Leigh J., et al.. (2004). Neuropsychological Test Performance in Healthy Volunteers Before and After Donepezil Administration. Journal of Psychopharmacology. 18(1). 102–108. 46 indexed citations
20.
Schoepp, Darryle D., Rebecca A. Wright, Louise R. Levine, Brenda Gaydos, & William Z. Potter. (2003). LY354740, an mGlu2/3 Receptor Agonist as a Novel Approach to Treat Anxiety/Stress. Stress. 6(3). 189–197. 175 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roy Tamura Breakdown of academic impact, for papers by László Tóthfalusi Breakdown of academic impact, for papers by Oleksandr Sverdlov Breakdown of academic impact, for papers by Hua Jin Breakdown of academic impact, for papers by Gregory G. Enas Breakdown of academic impact, for papers by Jacques Demotes‐Mainard Breakdown of academic impact, for papers by David J. DeBrota Breakdown of academic impact, for papers by Ch Davis Breakdown of academic impact, for papers by Mary F. Johnson Breakdown of academic impact, for papers by Haiyan Xu
Rankless by CCL
2026